Compass Ion Advisors LLC Acquires 9,057 Shares of Johnson & Johnson (NYSE:JNJ)

Compass Ion Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJFree Report) by 156.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,843 shares of the company’s stock after acquiring an additional 9,057 shares during the quarter. Compass Ion Advisors LLC’s holdings in Johnson & Johnson were worth $2,312,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Independent Advisor Alliance raised its holdings in Johnson & Johnson by 0.9% in the 2nd quarter. Independent Advisor Alliance now owns 153,337 shares of the company’s stock worth $25,380,000 after acquiring an additional 1,327 shares during the period. Cypress Wealth Services LLC increased its holdings in shares of Johnson & Johnson by 5.4% during the 2nd quarter. Cypress Wealth Services LLC now owns 9,725 shares of the company’s stock worth $1,547,000 after purchasing an additional 497 shares during the period. King Luther Capital Management Corp increased its holdings in shares of Johnson & Johnson by 0.3% during the 2nd quarter. King Luther Capital Management Corp now owns 643,435 shares of the company’s stock worth $106,501,000 after purchasing an additional 2,027 shares during the period. DORCHESTER WEALTH MANAGEMENT Co increased its holdings in shares of Johnson & Johnson by 0.6% during the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock worth $11,758,000 after purchasing an additional 414 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Johnson & Johnson by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 8,843,038 shares of the company’s stock worth $1,463,594,000 after purchasing an additional 430,445 shares during the period. Institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

Shares of NYSE JNJ opened at $158.90 on Thursday. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The company has a market cap of $382.52 billion, a PE ratio of 11.51, a P/E/G ratio of 2.68 and a beta of 0.53. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. The company has a 50-day moving average of $157.63 and a two-hundred day moving average of $159.24.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same period in the previous year, the firm posted $2.35 earnings per share. The company’s revenue was down 9.7% on a year-over-year basis. As a group, equities analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research reports. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, January 24th. Barclays lifted their target price on shares of Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a research report on Thursday, October 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday, January 23rd. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $180.00 in a research report on Friday, December 1st. Finally, Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $167.87.

Check Out Our Latest Stock Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.